ECSP18083519A - Inhibidores de bromodominios - Google Patents

Inhibidores de bromodominios

Info

Publication number
ECSP18083519A
ECSP18083519A ECSENADI201883519A ECDI201883519A ECSP18083519A EC SP18083519 A ECSP18083519 A EC SP18083519A EC SENADI201883519 A ECSENADI201883519 A EC SENADI201883519A EC DI201883519 A ECDI201883519 A EC DI201883519A EC SP18083519 A ECSP18083519 A EC SP18083519A
Authority
EC
Ecuador
Prior art keywords
bromodomines
inhibitors
formula
compounds
diseases
Prior art date
Application number
ECSENADI201883519A
Other languages
English (en)
Inventor
John PRATT
Bing Li
Le Wang
Michael Schrimpf
Keith F Mcdaniel
Steven D Fidanze
Lisa A Hasvold
Dachun Liu
George S Sheppard
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of ECSP18083519A publication Critical patent/ECSP18083519A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención proporciona compuestos de fórmula (I) donde R1, R2, R3, R4, R6, X1 y X2 tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, que incluyen enfermedades inflamatorias, cáncer y SIDA. También se proporcionan composiciones farmacéuticas que comprenden compuestos de fórmula (I).
ECSENADI201883519A 2016-04-15 2018-11-08 Inhibidores de bromodominios ECSP18083519A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016079362 2016-04-15

Publications (1)

Publication Number Publication Date
ECSP18083519A true ECSP18083519A (es) 2018-11-30

Family

ID=60042835

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201883519A ECSP18083519A (es) 2016-04-15 2018-11-08 Inhibidores de bromodominios

Country Status (38)

Country Link
US (3) US10633379B2 (es)
EP (2) EP3693369A3 (es)
JP (2) JP6978424B2 (es)
KR (1) KR102250415B1 (es)
CN (1) CN109071534B (es)
AR (1) AR108207A1 (es)
AU (2) AU2017251537B2 (es)
BR (1) BR112018071216A2 (es)
CA (1) CA3018802A1 (es)
CL (1) CL2018002924A1 (es)
CO (1) CO2018011064A2 (es)
CR (1) CR20180541A (es)
CY (1) CY1123025T1 (es)
DK (1) DK3442972T3 (es)
DO (1) DOP2018000227A (es)
EC (1) ECSP18083519A (es)
ES (1) ES2793239T3 (es)
HR (1) HRP20200728T1 (es)
HU (1) HUE050217T2 (es)
IL (1) IL261586B (es)
LT (1) LT3442972T (es)
MA (2) MA52814A (es)
MD (1) MD3442972T2 (es)
ME (1) ME03759B (es)
MX (1) MX2018012541A (es)
MY (1) MY190795A (es)
PE (1) PE20190472A1 (es)
PH (1) PH12018501920A1 (es)
PL (1) PL3442972T3 (es)
PT (1) PT3442972T (es)
RS (1) RS60302B1 (es)
RU (1) RU2741808C2 (es)
SG (1) SG11201808003RA (es)
SI (1) SI3442972T1 (es)
TW (3) TWI704147B (es)
UA (1) UA124764C2 (es)
UY (1) UY37205A (es)
WO (1) WO2017177955A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808003RA (en) * 2016-04-15 2018-10-30 Abbvie Inc Bromodomain inhibitors
EP3526210A4 (en) * 2016-10-14 2020-04-22 AbbVie Inc. BROMODOMAIN INHIBITORS
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. COMBINATION THERAPIES WITH EHMT2 INHIBITORS
JP2021533186A (ja) * 2018-07-25 2021-12-02 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN110964012B (zh) * 2018-09-29 2021-08-13 上海凌达生物医药有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
CA3133131A1 (en) * 2019-03-17 2020-09-24 Shanghai Ringene Biopharma Co., Ltd. Pyrrole amidopyridone compound, preparation method therefor and use thereof
GB201905721D0 (en) * 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2020232214A1 (en) * 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2021003310A1 (en) 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
US20230357240A1 (en) * 2020-12-01 2023-11-09 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel n-heterocyclic bet bromodomain inhibitor, and preparation method thereof and medical use thereof
CN115551861A (zh) * 2021-04-30 2022-12-30 成都苑东生物制药股份有限公司 一种新型brd4溴结构域protac蛋白降解剂、其制备方法及医药用途
IL309651A (en) 2021-06-29 2024-02-01 Tay Therapeutics Ltd History Pyrolopyridone is useful in the treatment of cancer
CN115611890A (zh) * 2021-07-15 2023-01-17 成都苑东生物制药股份有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA210876A (de) 1975-03-25 1979-01-15 Byk Gulden Lomberg Chem Fab Verfahren zur herstellung von neuen nidrofuryl- pyrazolderivaten
US4004012A (en) 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
US4072746A (en) 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
DE2845456A1 (de) 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
US4298609A (en) 1979-08-30 1981-11-03 Sterling Drug Inc. 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents
FR2478640A1 (fr) 1980-03-24 1981-09-25 Sanofi Sa Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique
US4304776A (en) 1980-04-28 1981-12-08 Sterling Drug Inc. 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics
US4305943A (en) 1980-04-28 1981-12-15 Sterling Drug Inc. 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
US4346221A (en) 1980-04-28 1982-08-24 Sterling Drug Inc. Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones
US4486431A (en) 1981-01-14 1984-12-04 Sterling Drug Inc. Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones
US4337253A (en) 1980-04-28 1982-06-29 Sterling Drug Inc. 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic
US4338446A (en) 1980-04-28 1982-07-06 Sterling Drug Inc. Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates
US4559352A (en) 1981-03-30 1985-12-17 Sterling Drug Inc. 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4465686A (en) 1981-09-08 1984-08-14 Sterling Drug Inc. 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation
US4515797A (en) 1981-09-08 1985-05-07 Sterling Drug Inc. 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
US4599423A (en) 1982-04-26 1986-07-08 Sterling Drug Inc. Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
DE3321012A1 (de) 1983-06-10 1984-12-13 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
US4666902A (en) 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB8323553D0 (en) 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US5217735A (en) 1986-10-22 1993-06-08 Wm. Wrigley Jr. Company Method of making chewing gum with delayed release ingredients
US5192563A (en) 1986-10-22 1993-03-09 Wm. Wrigley, Jr. Company Strongly mint-flavored chewing gums with reduced bitterness and harshness
US5112625A (en) 1989-02-15 1992-05-12 Wm. Wrigley Jr. Company Aqueous zein coated sweeteners and other ingredients for chewing gum
US4863745A (en) 1986-10-22 1989-09-05 Wm. Wrigley Jr. Company Chewing gum containing zein coated high-potency sweetener and method
US5221543A (en) 1986-10-22 1993-06-22 Firma Wilhelm Fette Gmbh Method of making a fast release stabilized aspartame ingredient for chewing gum
US4908371A (en) 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
US4919941A (en) 1987-12-18 1990-04-24 Wm. Wrigley Jr. Company Chewing gum containing delayed release protein sweetener and method
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1991012251A1 (en) 1990-02-19 1991-08-22 Chugai Seiyaku Kabushiki Kaisha Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ATE180475T1 (de) 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
CA2069877A1 (en) 1990-10-02 1992-04-03 Michio Nakanishi Ethynylphenyl derivative substituted by pyridazinone and medicament for circulatory disease containing the same as an effective ingredient
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CN1038249C (zh) 1991-08-28 1998-05-06 罗姆和哈斯公司 含有二氢哒嗪酮及其相关化合物的杀菌组合物
DE69229874T2 (de) 1991-10-09 1999-12-09 Syntex Inc Pyrido pyridazinon und pyridazinthionverbindungen mit pde iv inhibierender wirkung
US5716954A (en) 1991-10-09 1998-02-10 Syntex U.S.A. Inc. Benzopyridazinone and pyridopyridazinone compounds
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
EP0666851A4 (en) 1992-11-02 1995-08-30 Merck & Co. Inc. Substituted phthalazinones as nerotensin antagonists.
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JP3247540B2 (ja) 1994-05-12 2002-01-15 株式会社日立製作所 パケット化通信装置および切替え装置
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
JPH08337583A (ja) 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
JPH11508267A (ja) 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
AR003978A1 (es) 1995-08-25 1998-09-30 Rohm & Haas Composiciones de acidos grasos y piridazinonas que tienen efectos fungitoxicos sinergicos y metodos para controlar hongos.
KR100338144B1 (ko) 1996-09-13 2002-05-24 가마쿠라 아키오 티에노트리아졸로디아제핀 화합물 및 그의 약제학적 용도
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
EE9900435A (et) 1997-04-01 2000-04-17 Astra Pharmaceuticals Limited Püridiini uued derivaadid ja neid sisaldavad ravimkoostised
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
EP1043317B1 (en) 1997-11-19 2009-04-15 Kowa Co., Ltd. Pyridazine derivatives and medicaments containing them as active ingredient
SK8402000A3 (en) 1997-12-05 2001-03-12 Astrazeneca Uk Ltd Novel compounds
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6420367B1 (en) 1998-07-16 2002-07-16 Shionogo & Co., Ltd. Pyrimidine derivatives exhibiting antitumor activity
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
CN1297916A (zh) 1999-11-26 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸
DE10010423A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung
CN1315397A (zh) 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸
DE60038318D1 (de) 2000-07-04 2008-04-24 Robert John Eyre Erntemaschine
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003313169A (ja) 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2003249539A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007644A1 (ja) 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
US7226920B2 (en) 2003-08-06 2007-06-05 Vertex Pharmaceuticals Inc. Aminotriazole compounds useful as inhibitors of protein kinases
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
AU2004285449A1 (en) 2003-10-20 2005-05-12 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
SG115845A1 (en) 2004-03-31 2005-10-28 Univ Singapore Modulation of trip-br function and method of treating proliferative disorders
US7662832B2 (en) * 2004-09-03 2010-02-16 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2588949A1 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
CN101111480A (zh) 2004-12-01 2008-01-23 万有制药株式会社 取代的吡啶酮衍生物
JP2008533147A (ja) 2005-03-14 2008-08-21 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
US20060276496A1 (en) 2005-03-17 2006-12-07 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-Cytokine Heterocyclic Compounds
WO2006112331A1 (ja) 2005-04-13 2006-10-26 Dainippon Simitomo Pharma Co., Ltd. 新規縮合ピロール誘導体
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
WO2007008144A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008145A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CN101341124A (zh) 2005-12-14 2009-01-07 布里斯托尔-迈尔斯斯奎布公司 可用作丝氨酸蛋白酶抑制剂的6元杂环
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2097422A4 (en) 2006-11-13 2010-04-14 Lilly Co Eli THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS
WO2008133669A2 (en) 2006-12-14 2008-11-06 Gilead Sciences, Inc. Viral inhibitors
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
WO2008148034A1 (en) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
JP5451611B2 (ja) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ES2499017T3 (es) 2007-10-23 2014-09-26 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
WO2009054790A1 (en) 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
RU2531272C2 (ru) 2008-05-01 2014-10-20 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
EP2291373B1 (en) 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
EP2324018B1 (en) 2008-07-25 2013-09-04 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
WO2010127237A2 (en) 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2331525A4 (en) 2008-08-11 2013-01-02 Harvard College HALOFUGINONE ANALOGUES FOR THE INHIBITION OF ARNT SYNTHÉTASES AND USES THEREOF
NZ592961A (en) 2008-11-20 2012-09-28 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
SI2496582T1 (sl) 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
EP2955524A3 (en) 2009-11-05 2016-03-23 GlaxoSmithKline LLC Novel process
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102666774A (zh) 2009-11-11 2012-09-12 纳幕尔杜邦公司 在次级回路制冷系统中的制冷剂储存
MX2012012353A (es) 2010-04-23 2013-02-07 Kineta Inc Compuestos anti-virales.
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2788943A4 (en) 2011-12-07 2015-04-08 Affectiva Inc AFFECT-BASED EVALUATION OF THE EFFECT OF ADVERTISING
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20130188311A1 (en) 2012-01-23 2013-07-25 International Business Machines Corporation Cooling and noise-reduction apparatus
CA2870931A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
CN104620223B (zh) 2012-06-15 2018-11-16 英特尔公司 对于基于存储资历实现从不同线程进行转发的线程不可知的加载存储缓冲器
US20140094456A1 (en) 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
MX2015012005A (es) 2013-03-11 2016-04-04 Abbvie Inc Inhibidores de bromodominio.
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
EP2970276A1 (en) 2013-03-12 2016-01-20 AbbVie Inc. Dihydro-pyrrolopyridinone bromodomain inhibitors
BR112015022551A2 (pt) 2013-03-12 2017-07-18 Abbvie Inc inibidores de amido pirrol
JP6419735B2 (ja) 2013-03-12 2018-11-07 アッヴィ・インコーポレイテッド 四環系ブロモドメイン阻害剤
MX2015017963A (es) 2013-06-28 2016-11-10 Abbvie Inc Inhibidores de bromodominio.
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
CN103387576A (zh) * 2013-08-09 2013-11-13 中国药科大学 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途
JP6445574B2 (ja) * 2013-10-18 2018-12-26 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081246A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
AU2014363989A1 (en) 2013-12-09 2016-06-16 Abbvie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
CA2932040A1 (en) 2013-12-10 2015-06-18 Abbvie Inc. Bromodomain inhibitors
CA2946731C (en) 2014-04-23 2022-06-07 Incyte Corporation 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
JP6606444B2 (ja) 2016-03-10 2019-11-13 株式会社Ｓｕｂａｒｕ 車両用制御装置
MX2018012303A (es) 2016-04-15 2019-01-14 Syngenta Participations Ag Compuestos de piridazinona herbicida.
KR20230130747A (ko) 2016-04-15 2023-09-12 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
SG11201808003RA (en) * 2016-04-15 2018-10-30 Abbvie Inc Bromodomain inhibitors
MX2018012544A (es) 2016-04-15 2019-01-31 Bayer Animal Health Gmbh Nuevos derivados de pirazolopirimidina.
EP3468559B1 (en) 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
US20190134004A1 (en) 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
CA3039003A1 (en) 2016-10-14 2018-04-19 Abbvie Inc. Bromodomain inhibitors
EP3526210A4 (en) 2016-10-14 2020-04-22 AbbVie Inc. BROMODOMAIN INHIBITORS
WO2018095933A1 (en) 2016-11-22 2018-05-31 Université D'aix-Marseille (Amu) Method of prognosticating, or for determining the efficiency of a compound for treating cancer
CN110167939B (zh) 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
EP3609896A4 (en) 2017-04-14 2020-11-04 AbbVie Inc. BROMODOMAIN INHIBITORS
CN108976278B (zh) 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用

Also Published As

Publication number Publication date
IL261586A (en) 2018-10-31
CN109071534A (zh) 2018-12-21
RS60302B1 (sr) 2020-07-31
CN109071534B (zh) 2021-11-23
BR112018071216A2 (pt) 2019-02-05
WO2017177955A1 (en) 2017-10-19
CY1123025T1 (el) 2021-10-29
CR20180541A (es) 2019-07-04
MY190795A (en) 2022-05-12
US20200255426A1 (en) 2020-08-13
CA3018802A1 (en) 2017-10-19
AU2017251537A1 (en) 2018-09-13
TWI704147B (zh) 2020-09-11
EP3442972A4 (en) 2019-09-04
MA44674B1 (fr) 2020-06-30
MA44674A (fr) 2019-02-20
CO2018011064A2 (es) 2018-10-22
LT3442972T (lt) 2020-06-10
TW202122394A (zh) 2021-06-16
CL2018002924A1 (es) 2018-12-21
UA124764C2 (uk) 2021-11-17
PL3442972T3 (pl) 2020-07-27
EP3442972A1 (en) 2019-02-20
UY37205A (es) 2017-11-30
EP3442972B1 (en) 2020-03-04
AU2017251537B2 (en) 2020-10-08
EP3693369A2 (en) 2020-08-12
TWI764237B (zh) 2022-05-11
PT3442972T (pt) 2020-05-29
AU2021200101A1 (en) 2021-03-18
HUE050217T2 (hu) 2020-11-30
KR20180134350A (ko) 2018-12-18
HRP20200728T1 (hr) 2020-07-24
EP3693369A3 (en) 2020-09-09
US20190345153A1 (en) 2019-11-14
RU2018140061A3 (es) 2020-08-20
RU2741808C2 (ru) 2021-01-28
MA52814A (fr) 2022-04-27
TW202304907A (zh) 2023-02-01
DOP2018000227A (es) 2018-10-31
JP6978424B2 (ja) 2021-12-08
MD3442972T2 (ro) 2020-08-31
AR108207A1 (es) 2018-07-25
SI3442972T1 (sl) 2020-07-31
US20220017511A1 (en) 2022-01-20
MX2018012541A (es) 2019-01-17
PH12018501920B1 (en) 2019-06-24
ES2793239T3 (es) 2020-11-13
DK3442972T3 (da) 2020-04-27
SG11201808003RA (en) 2018-10-30
JP2019511482A (ja) 2019-04-25
PH12018501920A1 (en) 2019-06-24
KR102250415B1 (ko) 2021-05-11
IL261586B (en) 2021-05-31
US10633379B2 (en) 2020-04-28
PE20190472A1 (es) 2019-04-04
RU2018140061A (ru) 2020-05-15
ME03759B (me) 2021-04-20
JP2022024026A (ja) 2022-02-08
TW201738243A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
ECSP18083519A (es) Inhibidores de bromodominios
UY39630A (es) Inhibidores de bromodominios
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
DOP2015000308A (es) Inhibidores de bromodominios
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2015012431A (es) Pirrol amida como inhibidores.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
BR112019007631A2 (pt) inibidores de bromodomínios
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
MX2019004375A (es) Inhibidores de bromodominios.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam